Vivos Therapeutics Raises $3.5 Million through Stock Offering
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a renowned medical device and technology company, has announced a significant step to bolster its financial position. The company is set to undertake a registered direct offering of its common stock, alongside a private placement of short-term warrants aimed at raising approximately $3.5 million.
Details of the Offering
The plan involves selling 709,220 common shares at an offering price of $4.935 each. In addition, the private placement warrants are structured to be exercisable at $4.81 per share, potentially adding another $3.4 million in funding if fully exercised. While Vivos maintains a more substantial cash balance than debt, it is faced with the pressing challenge of rapidly depleting its cash reserves.
Financial Challenges Ahead
For Vivos Therapeutics, the need for this capital injection comes during a period of considerable financial strain. According to reports, the company recorded a negative EBITDA of $11.91 million over the last year, highlighting the urgent need for enhanced liquidity. The funds obtained from this offering are earmarked for working capital and general corporate purposes to stabilize operations.
Strategic Plans Following the Offering
As Vivos looks toward the future, the company aims to utilize the net proceeds from this funding to improve its operational capabilities. Vivos specializes in addressing sleep-related breathing disorders such as obstructive sleep apnea (OSA) and snoring through innovative and non-invasive methods. Their technology has successfully treated over 47,000 patients globally.
Recent Business Performance
In recent financial reports, Vivos showcased a 17% growth in total revenue, reaching $3.9 million for the most recent quarter. The growth has been supported primarily by escalating sales of their proprietary appliances and services, despite a noted decline in myofunctional therapy revenues. It's important to acknowledge, however, that the net loss for the same quarter increased to $2.6 million due to shifting warrant liabilities.
Organizational Developments and Shareholder Engagement
During their recent annual meeting, significant decisions were made with the support of shareholders, including the approval of their 2024 Omnibus Equity Incentive Plan and the election of six director nominees. This illustrates a robust engagement with stakeholders and a commitment to strategic governance.
Innovations and Future Directions
In alignment with its growth strategy, Vivos Therapeutics is revamping its sales and marketing approach. This includes establishing an alliance with Rivas Health and plans to open two new locations in Denver before the year's end. As part of these initiatives, the company aims to strengthen its revenue growth and enhance its cost structure.
Frequently Asked Questions
What is the purpose of Vivos Therapeutics' recent stock offering?
The offering aims to raise $3.5 million to bolster working capital and support general corporate purposes amidst financial challenges.
How many common shares is Vivos Therapeutics selling in the offering?
The company is offering 709,220 common shares priced at $4.935 each.
What are the potential implications of the private placement warrants?
The private placement warrants could generate an additional $3.4 million if exercised fully at $4.81 per share.
What recent growth has Vivos Therapeutics reported?
Vivos Therapeutics has reported a 17% increase in revenue for Q3 2024, indicating growth in sales of its devices.
What strategic initiatives is Vivos implementing for future growth?
The company plans to open new locations, form alliances, and revamp its sales and marketing strategies to drive revenue growth moving forward.
